Literature DB >> 1727824

Massive amounts of immunoreactive endothelin in human seminal fluid.

M L Casey1, W Byrd, P C MacDonald.   

Abstract

We found that immunoreactive endothelin (ET) is present in seminal fluid in very large amounts (500-5000 ng/L; quantification based on ET-1 standard). This immunoreactive ET was detected by use of a radioimmunoassay system in which the N-terminal portion of ET-1 and ET-2 (and big ET-1 and big ET-2) are recognized. Thus, the immunoreactive ET in seminal fluid may include the precursors of ET-1 or ET-2 (i.e., big ET) as well as metabolites of ET-1 or ET-2 in which the N-terminal region is intact. The levels of immunoreactive ET in seminal fluid from men with normal semen analyses and that in seminal fluid of vasectomized men were within the same range. Using a different radioimmunoassay system in which the C-terminal portion of ET-1, ET-2, and ET-3 is recognized, we found that the levels of immunoreactive ET were much lower (or undetectable). We speculate that bioactive ET may be produced and act to promote sperm transport in the male reproductive tract; thereafter, bioactive ET may be metabolized by membrane metalloendopeptidase (which is present in male reproductive tissues and semen) to immunoreactive, inactive products. Alternatively, big ET in seminal fluid may be processed in tissues of the female internal genitalia to bioactive ET, which could act to promote sperm transport through the uterine cavity by stimulating myometrial contractions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727824     DOI: 10.1210/jcem.74.1.1727824

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Pharmacological characterization of endothelin receptor subtypes in the guinea-pig prostate gland.

Authors:  W A Lau; S L Cox; J N Pennefather; F J Mitchelson
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 2.  Endothelin receptor antagonists.

Authors:  Joel B Nelson
Journal:  World J Urol       Date:  2005-01-15       Impact factor: 4.226

3.  Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.

Authors:  Gregory A Clines; Khalid S Mohammad; Yongde Bao; Owen W Stephens; Larry J Suva; John D Shaughnessy; Jay W Fox; John M Chirgwin; Theresa A Guise
Journal:  Mol Endocrinol       Date:  2006-10-26

4.  Endothelin receptor A blockade enhances taxane effects in prostate cancer.

Authors:  Ardavan Akhavan; Kevin H McHugh; Georgi Guruli; Robert R Bies; William C Zamboni; Sandra A Strychor; Joel B Nelson; Beth R Pflug
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

5.  A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.

Authors:  William R Schelman; Glenn Liu; George Wilding; Thomas Morris; De Phung; Robert Dreicer
Journal:  Invest New Drugs       Date:  2009-09-19       Impact factor: 3.850

Review 6.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

7.  A transformed murine Leydig cell line expresses the ETA receptor subtype.

Authors:  A Ergul; M K Glassberg; M E Freeman; D Puett
Journal:  Mol Cell Biochem       Date:  1994-07-13       Impact factor: 3.396

8.  Inositol lipid-mediated signalling in response to endothelin and ATP in the mammalian testis.

Authors:  S A Rudge; P J Hughes; G R Brown; R H Michell; C J Kirk
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

9.  Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles.

Authors:  Christine J Weydert; Alison K Esser; Ruth A Mejia; Justin M Drake; J Matthew Barnes; Michael D Henry
Journal:  Cancer Biol Ther       Date:  2009-04       Impact factor: 4.742

10.  Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption.

Authors:  J W Chiao; B S Moonga; Y M Yang; R Kancherla; A Mittelman; J R Wu-Wong; T Ahmed
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.